دورية أكاديمية
A simple score to estimate the likelihood of pseudoprogression vs. recurrence following stereotactic radiosurgery for brain metastases: The Bergen Criteria.
| العنوان: | A simple score to estimate the likelihood of pseudoprogression vs. recurrence following stereotactic radiosurgery for brain metastases: The Bergen Criteria. |
|---|---|
| المؤلفون: | Skeie BS; Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway., Enger PØ; Department of Neurosurgery, Stavanger University Hospital, Stavanger, Norway., Knisely J; Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA., Pedersen PH; Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway., Heggdal JI; Department of Oncology and Medical Physics, Haukeland University Hospital, Bergen, Norway., Eide GE; Department of Global Public Health and Primary Care, University of Bergen, Norway.; Centre for Clinical Research, Haukeland University Hospital, Bergen, Norway., Skeie GO; Department of Neurology, Haukeland University Hospital, Bergen, Norway. |
| المصدر: | Neuro-oncology advances [Neurooncol Adv] 2020 Mar 10; Vol. 2 (1), pp. vdaa026. Date of Electronic Publication: 2020 Mar 10 (Print Publication: 2020). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Oxford University Press Country of Publication: England NLM ID: 101755003 Publication Model: eCollection Cited Medium: Internet ISSN: 2632-2498 (Electronic) Linking ISSN: 26322498 NLM ISO Abbreviation: Neurooncol Adv Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: [Oxford] : Oxford University Press, [2019]- |
| مستخلص: | Background: A major challenge in the follow-up of patients treated with stereotactic radiosurgery (SRS) for brain metastases (BM) is to distinguish pseudoprogression (PP) from tumor recurrence (TR). The aim of the study was to develop a clinical risk assessment score. Methods: Follow-up images of 87 of 97 consecutive patients treated with SRS for 348 BM were analyzed. Of these, 100 (28.7%) BM in 48 (53.9%) patients responded with either TR ( n = 53, 15%) or PP ( n = 47, 14%). Differences between the 2 groups were analyzed and used to develop a risk assessment score (the Bergen Criteria). Results: Factors associated with a higher incidence of PP vs. TR were as follows: prior radiation with whole brain radiotherapy or SRS ( P = .001), target cover ratio ≥98% ( P = .048), BM volume ≤2 cm 3 ( P = .054), and primary lung cancer vs. other cancer types ( P = .084). Based on the presence (0) or absence (1) of these 5 characteristics, the Bergen Criteria was established. A total score <2 points was associated with 100% PP, 2 points with 57% PP and 43% TR, 3 points with 57% TR and 43% PP, whereas >3 points were associated with 84% TR and 16% PP, P < .001. Conclusion: Based on 5 characteristics at the time of SRS the Bergen Criteria could robustly differentiate between PP vs. TR following SRS. The score is user-friendly and provides a useful tool to guide the decision making whether to retreat or observe at appropriate follow-up intervals. (© The Author(s) 2020. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.) |
| References: | Clin Neurosurg. 2010;57:160-5. (PMID: 21280510) Lancet. 2004 May 22;363(9422):1665-72. (PMID: 15158627) J Clin Oncol. 2017 Jul 20;35(21):2439-2449. (PMID: 28640707) Radiother Oncol. 2019 Jan;130:104-112. (PMID: 30241791) Radiol Med. 2018 Jul;123(7):545-552. (PMID: 29508242) J Neurosurg. 2017 Mar;126(3):708-725. (PMID: 27058206) Neurosurgery. 2008 Nov;63(5):898-903; discussion 904. (PMID: 19005380) Neuro Oncol. 2017 Oct 1;19(10):1391-1397. (PMID: 28472527) Neuro Oncol. 2016 Jun;18(6):873-80. (PMID: 26688076) Cureus. 2018 Jan 8;10(1):e2037. (PMID: 29541558) AJNR Am J Neuroradiol. 2011 Nov-Dec;32(10):1885-92. (PMID: 21920854) J Neurosurg. 2017 Nov;127(5):1007-1014. (PMID: 28059663) Neurosurg Rev. 2014 Apr;37(2):193-201; discussion 201. (PMID: 24233257) J Neurosurg. 2015 Aug;123(2):373-86. (PMID: 25978710) Clin Transl Oncol. 2018 Aug;20(8):939-953. (PMID: 29218626) J Neurosurg. 2003 May;98(5):1056-64. (PMID: 12744366) Neurosurgery. 2010 Mar;66(3):486-91; discussion 491-2. (PMID: 20173543) Cancer Immunol Res. 2016 Mar;4(3):179-82. (PMID: 26701266) World Neurosurg. 2013 Mar-Apr;79(3-4):525-36. (PMID: 22120263) J Neurosurg. 2014 Sep;121(3):564-9. (PMID: 24878286) World Neurosurg. 2011 May-Jun;75(5-6):684-91; discussion 598-603. (PMID: 21704936) J Neurosurg. 2006 Jun;104(6):907-12. (PMID: 16776334) Front Oncol. 2018 Sep 28;8:395. (PMID: 30324090) Front Oncol. 2018 Sep 27;8:414. (PMID: 30319977) Brain Tumor Pathol. 2008;25(2):51-8. (PMID: 18987829) Eur J Nucl Med Mol Imaging. 2013 Apr;40(4):615-35. (PMID: 23232505) Curr Oncol Rep. 2018 Nov 9;20(11):91. (PMID: 30413981) Neuro Oncol. 2017 Sep 1;19(9):1271-1278. (PMID: 28204572) |
| فهرسة مساهمة: | Keywords: brain metastases; pseudoprogression; radiation necrosis; stereotactic radiosurgery; tumor recurrence |
| تواريخ الأحداث: | Date Created: 20200710 Latest Revision: 20220415 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC7212847 |
| DOI: | 10.1093/noajnl/vdaa026 |
| PMID: | 32642686 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2632-2498 |
|---|---|
| DOI: | 10.1093/noajnl/vdaa026 |